Speaker illustration

Doctor Kevin Damman

University Medical Center Groningen, Groningen (Netherlands (The))

Member of:

Heart Failure Association

Dr Kevin Damman, MD, PhD, FHFA, studied medicine at the University of Groningen, The Netherlands and received his PhD in 2009 entitled “Cardiorenal Interaction in Heart Failure”. Dr Damman is a clinical cardiologist, head of the heart transplant and ventricular assist device program at the University Medical Center Groningen. His interests include advanced and acute heart failure. Current research interests are focused on improving treatment of acute heart failure patients, including SGLT2-inhibition in (acute) heart failure and the role of the kidney in the process of cardiorenal interaction. He is principle investigator of the EMPA-RESPONSE-AHF study on empagliflozin in acute heart failure and is part of the steering committee of the ADVOR trial investigating acetazolamide in acute heart failure. Dr Damman is associate editor of the European Journal of Heart Failure and is member of the working groups on Cardiorenal Dysfunction and Acute Heart Failure from the HFA.

Scientific wrap-up

Event: Heart Failure 2022

Topic: Chronic Heart Failure

Session type: Special Session


Challenges and opportunities in patients with left ventricular assist devices

Event: Heart Failure 2022

Topic: Device Therapy

Session type: Symposium


Clinical Case Corner 2 - The horizon in pharmacological therapies, interventions & device

Event: Heart Failure 2017 - 4th World Congress on Acute Heart Failure

Topic: Miscellaneous

Session type: Clinical Case Posters


This platform is supported by

logo Novo Nordisk